Clinical trials: No Conditions
No Specific Conditions Under Study. Primary Focus: Adult Subjects Who Require PICC Placement
Assessment of the Precision of the Sherlock 3CG Tip Positioning System
Phase I determine the location of the peripherally inserted central catheter (PICC) tip upon observation of maximum p-wave amplitude Phase II determine the precision of PICC placement in the Sherlock 3CG group versus the standard…
- Trial name
- STAT-PICC (NCT01275430)
- Testing
- Sherlock 3CG, Blind Placement
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- C. R. Bard
End Stage Renal Disease Requiring Hemodialysis
Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug
Patients whose kidneys are no longer able to work as they should and require treatment to filter wastes from the blood (hemodialysis) are at high risk for blood clots that form in blood vessels (thrombosis) blocking blood flow…
- Trial name
- RE-THINc ESRD (NCT04534114)
- Testing
- Fesomersen sodium (BAY2976217)
- Where
- 69 sites in United States, Belgium and 13 more
- Volunteers
- 307 people
- Sponsor
- Bayer
Mild to Moderate Chronic Low Back Pain
The Efficacy of the no!no!Back for Chronic Low Back Pain
This pilot study is designed to evaluate the efficacy of the no!no!Back continuous passive motion device in relieving of mild to moderate non-specific low back pain.
- Trial name
- LBP-1 (NCT01620281)
- Testing
- no!no!Back
- Where
- Israel
- Volunteers
- 36 people
- Sponsor
- Radiancy
Myelogenous Leukemia, Acute, Leukemia, Lymphocytic, Acute
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
This study of SCH 900776 (MK-8776) will evaluate its safety and tolerability when given in combination with cytarabine to participants with acute leukemias.
- Conditions
- Myelogenous Leukemia, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Myelogenous Leukemia, Chronic, Aggressive Phase
- Trial name
- NCT00907517
- Testing
- MK-8776, Cytarabine
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Retinitis Pigmentosa, Retinitis
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
The purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (MCO-010).
- Conditions
- Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases
- Trial name
- RESTORE (NCT04945772)
- Testing
- Gene Therapy Product-MCO-010
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 27 people
- Sponsor
- Nanoscope Therapeutics Inc.
Age-Related Macular Degeneration
Photodynamic Therapy in Occult-Only Lesions (POOL)
Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye.
- Trial name
- NCT00135837
- Testing
- Verteporfin for injection
- Where
- Switzerland
- Volunteers
- 202 people
- Sponsor
- Novartis
Subarachnoid Hemorrhage
Efficacy and Safety Assessment for a New UV-protected Pump Infusion Line in Intravenous Infusion Therapy
To verify the efficacy and safety of Original Perfusor Line (Art.No.8723017) in infusion therapy in Patients with light sensitive drug infusion.
- Trial name
- NCT04309708
- Testing
- Nimodipine pump infusion
- Where
- 5 sites in China
- Volunteers
- 300 people
- Sponsor
- B. Braun Medical International Trading Company Ltd.
Non 24 Hour Sleep Wake Disorder
Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception
The purpose of this study is to evaluate the safety of a one year open-label treatment of tasimelteon in male and female subjects with Non-24-Hour Sleep-Wake Disorder.
- Trial name
- NCT01218789
- Testing
- tasimelteon
- Where
- 7 sites in France
- Volunteers
- 140 people
- Sponsor
- Vanda Pharmaceuticals
Postoperative Nausea and Vomiting
Study of APD421 as PONV Treatment (no Prior Prophylaxis)
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have not had prior PONV…
- Trial name
- NCT02449291
- Testing
- APD421
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 568 people
- Sponsor
- Acacia Pharma Ltd
Healthy
Pharmacokinetic Interaction Between Ibuprofen and Acetaminophen, Tablets Administered Individually or in Combination
This study was carried out in the Clinical and Analytical Unit of the Pharmacology and Toxicology Department of the Faculty of Medicine of the Autonomous University of Nuevo León, with the aim of comparing the bioavailability…
- Trial name
- NCT05428306
- Testing
- A1: Ibuprofen/Acetaminophen Fixed dose combination (Laboratorios Silanes S.A. de C.V.), A2: Ibuprofen (Motrin®, Pfizer S.A. de C.V.), A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)
- Where
- Mexico
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
No Condition, Healthy Individuals
Microneedle-based ISF Sampling Technique
This clinical investigation aims to evaluate the performance and safety of the PELSA system, a hollow microneedle-based medical device designed for the collection of dermal interstitial fluid (dISF) from human skin.
- Trial name
- MIST (NCT07882225)
- Testing
- PELSA System
- Where
- Germany
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Ascilion AB
Seizures, Epileptic
An Observational Study of the Safety of Topiramate in Adults and Children With Epilepsy
The purpose of this observational study is to evaluate the safety of topiramate in adults and children with epilepsy (or seizures) who have not received or have not responded to treatment with previous antiepileptic medication.
- Trial name
- NCT00297323
- Testing
- Topiramate
- Volunteers
- 80 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Chronic Hepatitis C, Liver Fibrosis
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)
The objective of the study is to evaluate the safety and efficacy of PEG-Intron versus no treatment for the prevention of fibrosis progression in adult participants with moderate to severe liver fibrosis secondary to chronic…
- Trial name
- NCT00049842
- Testing
- peginterferon alfa-2b (SCH 54031)
- Volunteers
- 540 people
- Sponsor
- Merck Sharp & Dohme LLC
No Disease or Condition is Being Studied, Evaluating a Brief Intervention
Evaluation of Virtual Reality in Hazmat Training
Type of study: Two-group comparison. Main question it aims to answer: Does the use of virtual reality emergency scenarios provide a practical and effective tool to supplement traditional instructor-led training for first…
- Conditions
- No Disease or Condition is Being Studied, Evaluating a Brief Intervention, Does Virtual Reality Aid in Hazmat Training
- Trial name
- NCT06113406
- Testing
- Classroom Training, Virtual Reality Training
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- MetaMedia Training International, Inc.
Chronic Hepatitis C
Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy
This Phase 3 clinical study is designed to evaluate the safety, tolerability, and efficacy of two dose levels of Infergen (interferon alfacon-1, CIFN) plus Ribavirin administered daily for 48 weeks and no treatment in patients…
- Trial name
- NCT00162734
- Testing
- Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks
- Volunteers
- 144 people
- Sponsor
- Bausch Health Americas, Inc.
Bronchiolitis
Evaluation of the Safety and Tolerability of Nitric Oxide (NO) Via Inhalation to Subjects With Bronchiolitis
Prospective, Double Blind, Randomized Single-Center, Evaluation of Safety and Tolerability of Nitric Oxide Given Intermittently via Inhalation to Subjects with Bronchiolitis-Phase IIa Bronchiolitis is defined as an infection of…
- Trial name
- NCT01768884
- Testing
- Nitric Oxide
- Where
- Israel
- Volunteers
- 43 people
- Sponsor
- Beyond Air Inc.
No Disease State or Condition
Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 on Gingival Mucosal Tissue in Normal Volunteers
The purpose of this study is to determine if the topical application to gingival tissue of the combination of benzocaine and tetracaine has a longer duration of local anesthetic activity than benzocaine alone.
- Trial name
- NCT03233737
- Testing
- One spray CTY-5339-A, One spray CTY-5339-CB, One spray CTY-5339-P
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Cetylite Industries
Arrhythmias, Cardiac
CanGaroo® Registry Study
A Multi-Center Registry Evaluating Participants Who Receive CanGaroo Envelope or No Envelope During their CIED Implantation
- Trial name
- NCT04846127
- Testing
- CanGaroo Envelope
- Where
- 23 sites in United States
- Volunteers
- 500 people
- Sponsor
- Elutia Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
This is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main aim of this study is to determine the percentage of participants with a clinical (Part 1) or platelet (Part 2)…
- Trial name
- NCT05714969
- Testing
- TAK-755
- Where
- 22 sites in United States, Austria and 4 more
- Volunteers
- 29 people
- Sponsor
- Takeda
Infections, Herpesviridae
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.
- Trial name
- NCT00116844
- Testing
- Valaciclovir
- Where
- 17 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline